Qiping Zhao

This inventor holds 21 USPTO granted patents and 13 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Polypeptide Variants. Top assignee: Halozyme, Inc.. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Qiping Zhao. Retrieved from https://idiyas.com/inventor/qiping-zhao

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 21 (Patent Applications = 13)

% Patents Active = 95.2

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 4.0

ph-index = 4

Forward Citations = 84(Granted Patents)

Company Filing History:

21 out of 85

Halozyme, Inc.

patents

Years Active: 2016-2026

Loading Chart...

Areas of Expertise:

PH20 Polypeptide

Variants

Formulations

Modifications

Biotechnology

Protein Engineering

Pharmaceuticals

Peptide Design

Biologic Applications

Therapeutics

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12600959 - PH20 polypeptide variants, formulations and uses thereof (2026-04-14),

2. 12371685 - PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereof (2025-07-29),

3. 12264345 - PH20 polypeptide variants, formulations and uses thereof (2025-04-01),

4. 12195773 - PH20 polypeptide variants, formulations and uses thereof (2025-01-14),

5. 12152262 - PH20 polypeptide variants, formulations and uses thereof (2024-11-26),

6. 12123035 - PH20 polypeptide variants, formulations and uses thereof (2024-10-22),

7. 12110520 - PH20 polypeptide variants, formulations and uses thereof (2024-10-08),

8. 12104185 - PH20 polypeptide variants, formulations and uses thereof (2024-10-01),

9. 12104184 - PH20 polypeptide variants, formulations and uses thereof (2024-10-01),

10. 12091692 - PH20 polypeptide variants, formulations and uses thereof (2024-09-17),

11. 12077791 - PH20 polypeptide variants with a modification at position 309 of the PH20 polypeptide and a method of making thereof (2024-09-03),

12. 12060590 - PH20 polypeptide variants, formulations and uses thereof (2024-08-13),

13. 12054758 - PH20 polypeptide variants, formulations and uses thereof (2024-08-06),

14. 12049652 - PH20 polypeptide variants, formulations and uses thereof (2024-07-30),

15. 12037618 - PH20 polypeptide variants, formulations and uses thereof (2024-07-16),

Title: Qiping Zhao: Innovator in Hyaluronidase Polypeptide Research

Introduction

Qiping Zhao is a prominent inventor based in San Diego, CA, recognized for his significant contributions to the field of biotechnology. With a total of 19 patents to his name, he has played a crucial role in advancing medical formulations and treatments through his research and innovations.

Latest Patents

Among his latest enhancements, Qiping Zhao has focused on PH20 polypeptide variants and their applications. His patents include modified PH20 hyaluronidase polypeptides, which are designed to exhibit increased stability and/or enhanced activity. He has also developed various compositions and formulations that utilize these innovative polypeptides, thereby offering new possibilities for medical applications.

Career Highlights

Qiping Zhao currently contributes his expertise at Halozyme, Inc., a company renowned for its innovation in the field of drug delivery and therapeutic development. His work has paved the way for advancements that hold great potential for improving patient outcomes in various clinical settings.

Collaborations

Throughout his career, Qiping has collaborated with esteemed colleagues, including Ge Wei and Robert James Connor. Together, they have driven research initiatives that expand the boundaries of current medicinal practices and enhance therapeutic formulations.

Conclusion

Qiping Zhao's innovative efforts in the development of modified PH20 polypeptide variants underscore his commitment to advancing medical science. With a strong portfolio of patents and collaboration with other professionals, he continues to make significant strides in the field, contributing valuable insights and advancements to the biopharmaceutical industry.

Profile summary based on public USPTO records.